Cart
sales@molnova.com
GRGDSPK acetate
CAS No. 144027-77-0
GRGDSPK acetate( —— )
Catalog No. M36639 CAS No. 144027-77-0
GRGDSPK acetate shows inhibitory activity against integrin-fibronectin binding and can be used in research on integrins in bone formation and resorption.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 179 | In Stock |
|
| 10MG | 263 | In Stock |
|
| 25MG | 392 | In Stock |
|
| 50MG | 539 | In Stock |
|
| 100MG | 736 | In Stock |
|
| 200MG | 986 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGRGDSPK acetate
-
NoteResearch use only, not for human use.
-
Brief DescriptionGRGDSPK acetate shows inhibitory activity against integrin-fibronectin binding and can be used in research on integrins in bone formation and resorption.
-
DescriptionGRGDSPK acetate shows inhibitory activity against integrin-fibronectin binding and can be used in research on integrins in bone formation and resorption.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMembrane Transporter/Ion Channel
-
TargetBeta Amyloid
-
RecptorBeta Amyloid
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number144027-77-0
-
Formula Weight775.81
-
Molecular FormulaC30H53N11O13
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(C)(O)=O.C([C@@H](NC([C@@H](NC(CNC([C@H](CCCNC(=N)N)NC(CN)=O)=O)=O)CC(O)=O)=O)CO)(=O)N1[C@H](C(N[C@@H](CCCCN)C(O)=O)=O)CCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Buntanetap
Buntanetap ((+)-Phenserine) is an orally active inhibitor of polyneurotoxic proteins (TINAPs) for the study of neurological disorders, endocrine and metabolic disorders, and cardiovascular diseases.
-
β-Amyloid 35-42
β-Amyloid (35-42) is a peptide consisting of amino acid of 35 to 42 of beta amyloid protein.
-
Scyllo-Inositol
Scyllo-Inositol is one of the inositol stereoisomers rare in the nature and expected as a promising disease-modifying therapeutic agent for Alzheimer's disease.
